IA
NMRA icon

IFP Advisors’s Neumora Therapeutics NMRA Stock Holding History

IFP Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32
Closed -$58 – 4988
2025
Q3 		$58 Sell
32
-49
-60% -$79 ﹤0.01% 4639
2025
Q2 		$60 Buy
+81
New +$61 ﹤0.01% 4784
2025
Q1 		– Hold
0
– – – 4282
2024
Q4 		– Hold
0
– – – 4368

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

IFP Advisors's NMRA Position: Q4 2025 in Review

IFP Advisors sold out of Neumora Therapeutics (NMRA) in Q4 2025, closing a stake of 32 shares — an estimated $58 sold.

IFP Advisors first reported a position in NMRA in Q2 2025 and held it in 2 quarters. The position peaked at $60 in Q2 2025. 102 funds tracked by Wall St. Rank hold NMRA as of Q4 2025.

  • IFP Advisors reported no remaining Neumora Therapeutics position as of Q4 2025 after selling out during the quarter.
  • IFP Advisors sold 32 Neumora Therapeutics shares in Q4 2025, an estimated $58.
  • IFP Advisors first reported a position in Neumora Therapeutics in Q2 2025 and held it in 2 quarters.
  • IFP Advisors's Neumora Therapeutics position peaked at $60 in Q2 2025.
  • 102 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.